1. Show article details.

    Survey Finds Industry Taking Action to Address Challenges from Rapid Move to Decentralized Trials Amid COVID-19

    PR Newswire – 8:00 AM ET 10/14/2021

    PLEASANTON, Calif. Today, most sponsors and CROs use some type of decentralized technology, up 59 percentage points from before the pandemic.

  2. Show article details.

    Veeva Vault CDMS Delivers Agility and Speed for Oncology Trials

    PR Newswire – 8:00 AM ET 10/13/2021

    PLEASANTON, Calif. Oncology trials are difficult to execute and demonstrate higher rates of amendment than other studies. With Vault CDMS, data managers can make mid-study amendments without data migration or downtime.

  3. Show article details.

    More Than 50 Companies Modernizing Pharmacovigilance with Veeva Vault Safety Suite

    PR Newswire – 8:00 AM ET 10/13/2021

    PLEASANTON, Calif. Organizations of all sizes are modernizing pharmacovigilance with the Vault Safety Suite to drive end-to-end processes through better collaboration. "More companies are adopting Veeva Vault Safety Suite applications to drive faster, more efficient case management," said Kelly Traverso, vice president, Veeva Vault Safety strategy.

  4. Show article details.

    Veeva's TMF Bot Automates Processes for Faster Clinical Trials

    PR Newswire – 7:03 AM ET 10/13/2021

    PLEASANTON, Calif. "We are processing documents more quickly and more efficiently with Veeva Vault eTMF and the TMF Bot," said Stephen van Arcken, senior clinical oversight lead at Cerevel Therapeutics. Automating trial processes with the TMF Bot can reduce the administrative burden on study teams and help alleviate the challenges of misfiled or misclassified documents within the TMF.

  5. Show article details.

    BRIEF-Veeva Systems Inc Announces Digital Trials Platform Connecting Patients, Sites, And Sponsors

    Reuters – 8:11 AM ET 10/12/2021

    Veeva Systems Inc (VEEV): * VEEVA ANNOUNCES DIGITAL TRIALS PLATFORM CONNECTING PATIENTS, SITES, AND SPONSORS Source text for Eikon: Further company coverage:

  6. Show article details.

    Veeva Announces Digital Trials Platform Connecting Patients, Sites, and Sponsors

    PR Newswire – 8:00 AM ET 10/12/2021

    PLEASANTON, Calif. The comprehensive product offering includes the following core solutions: Each of these solutions are built for the unique needs of patients, sites, and sponsors but connected for seamless execution and flow of data across all stakeholders. The patient consent process provides a good illustration of how the Veeva Digital Trials Platform drives collaboration and data flow.

  7. Show article details.

    Veeva to Host Virtual Financial Analyst and Investor Day on Oct. 28, 2021

    PR Newswire – 4:05 PM ET 10/06/2021

    PLEASANTON, Calif. Veeva (VEEV) will broadcast the presentations live on the company's investor relations website, ir.veeva.com, where a link to the archived webcast will also be available after the event. About Veeva SystemsVeeva (VEEV) is the global leader in cloud software for the life sciences industry.

  8. Show article details.

    Celerion Transforms the Consent Experience for Sites and Patients with Veeva eConsent

    PR Newswire – 7:03 AM ET 10/06/2021

    PLEASANTON, Calif. "COVID-19 limited our time with participants, so we needed new and digital ways to keep our studies moving forward while remaining fully compliant with regulatory requirements regarding obtaining proper consent," said Staci McDonald, executive director, scientific clinical operations at Celerion.

  9. Show article details.

    BRIEF-Leo Pharma And Veeva Systems Partner For Patient-Centric Digital Trials

    Reuters – 9:33 AM ET 09/29/2021

    Veeva Systems Inc (VEEV): * LEO PHARMA AND VEEVA SYSTEMS PARTNER FOR PATIENT-CENTRIC DIGITAL TRIALS Source text for Eikon: Further company coverage:

  10. Show article details.

    LEO Pharma and Veeva Systems Partner for Patient-centric Digital Trials

    PR Newswire – 8:00 AM ET 09/29/2021

    BALLERUP, Denmark and PLEASANTON, Calif. Building on its success with the Veeva Clinical Operations Suite, LEO Pharma will complete its standardization on existing Veeva (VEEV) clinical technology, be an early adopter of future Veeva (VEEV) solutions, and help to shape the Veeva (VEEV) digital trials roadmap.

  11. Show article details.

    BRIEF-Veeva Announces New Application To Optimize Quality Control Labs

    Reuters – 7:05 AM ET 09/28/2021

    Veeva Systems Inc (VEEV): * VEEVA ANNOUNCES NEW APPLICATION TO OPTIMIZE QUALITY CONTROL LABS Source text for Eikon: Further company coverage:

  12. Show article details.

    Veeva Announces New Application to Optimize Quality Control Labs

    PR Newswire – 7:03 AM ET 09/28/2021

    PLEASANTON, Calif. "There is a significant opportunity to bring together lab and quality processes for faster, more accurate lab testing," said Brian Brunner, managing director at Accenture. Vault LIMS will enable easy information sharing between lab users and partners and deliver real-time data for more informed decision-making.

  13. Show article details.

    BRIEF-Convatec Selects Veeva Vault CDMS For Biomarker Study In Wound Infections

    Reuters – 7:18 AM ET 09/23/2021

    Veeva Systems Inc (VEEV): * CONVATEC SELECTS VEEVA VAULT CDMS FOR BIOMARKER STUDY IN WOUND INFECTIONS Source text for Eikon: Further company coverage:

  14. Show article details.

    ConvaTec Selects Veeva Vault CDMS for Biomarker Study in Wound Infections

    PR Newswire – 7:03 AM ET 09/23/2021

    PLEASANTON, Calif. To aid accurate and timely detection of wound infection in clinical practice, ConvaTec and partners have developed a new infection biomarker detection technology based on the combined measurement of the following three biomarkers: wound pH, activity of human neutrophil elastase, and myeloperoxidase host enzymes.

  15. Show article details.

    Emmes Standardizes on Veeva Development Cloud to Streamline Product Development

    PR Newswire – 7:03 AM ET 09/20/2021

    ROCKVILLE, Md. and PLEASANTON, Calif. "Our strategic partnership with Veeva (VEEV) empowers us to streamline how we work, improve visibility and oversight, and run faster, more cost-effective research programs," said Dr. Christine Dingivan, chief executive officer at Emmes.

  16. Show article details.

    Veeva Announces New Application to Speed Validation Execution

    PR Newswire – 7:03 AM ET 09/15/2021

    PLEASANTON, Calif. "Manual validation processes are ineffective, draining resources and increasing operational cost," said Mike Jovanis, vice president of Veeva Vault Quality. Vault Validation Management will reduce manual processes and eliminate silos for better tracking and alignment across validation activities and projects.

  17. Show article details.

    Life Sciences Visionaries and Innovators Come Together at Veeva Summit Connect

    PR Newswire – 7:03 AM ET 09/14/2021

    PLEASANTON, Calif. Summit Connect is designed to maximize knowledge sharing through interactive sessions and roundtables, featuring more than 75 sessions with global pharmaceutical and biotech leaders at the forefront of transformational change in clinical, regulatory, safety, and quality.

  18. Show article details.

    Unilever, Reckitt, BASF, Estée Lauder, HBS, AWS, and Kearney Among Speakers at Veeva's Global Summit for Consumer Goods and Chemical Industries

    PR Newswire – 7:03 AM ET 09/08/2021

    PLEASANTON, Calif. The virtual event will feature more than 15 sessions with quality, regulatory, legal, marketing, and IT experts across North America and Europe.

  19. Show article details.

    BRIEF-Veeva Announces Fiscal 2022 Second Quarter Results

    Reuters – 4:37 PM ET 09/01/2021

    Veeva Systems Inc (VEEV): * VEEVA ANNOUNCES FISCAL 2022 SECOND QUARTER RESULTS. * SEES Q3 NON-GAAP EARNINGS PER SHARE $0.87 TO $0.88. * Q2 NON-GAAP EARNINGS PER SHARE $0.94. * Q2 EARNINGS PER SHARE $0.67. * SEES Q3 REVENUE $464 MILLION TO $466 MILLION. * SEES FY REVENUE $1.83 BILLION TO $1.835 BILLION. * Q2 REVENUE $455.6 MILLION VERSUS REFINITIV IBES ESTIMATE OF $451.9 MILLION.

  20. Show article details.

    Veeva Announces Fiscal 2022 Second Quarter Results

    PR Newswire – 4:05 PM ET 09/01/2021

    PLEASANTON, Calif. "Thanks to the team and the trust of our customers, it was another great quarter," said CEO Peter Gassner. "Rapid innovation is driving expansion in existing markets and significant early traction in newer areas like CDMS and safety as we start to realize the major potential of Veeva Development Cloud."

Page:

Today's and Upcoming Events

  • Nov
    29

    VEEV to announce Q3 earnings (Unconfirmed)

Past Events (last 90 days)

  • Sep
    01

    VEEV announced Q2 earnings.

Data provided by Thomson Reuters © 2021

Technical Events

Technical Analysis

PROVIDED BY TRADING CENTRAL
As with all your investments through Fidelity, you must make your own determination whether an investment is appropriate for you. Fidelity is not recommending or endorsing this security by making it available to customers. You should conduct research and perform a thorough investigation as to the characteristics of any securities you intend to purchase. Before investing, you should read the prospectus, offering circular, indenture, or similar document carefully for a full description of the product, including its features and risks, to determine whether it is an appropriate investment for your investment objectives, risk tolerance, financial situation and other individual factors, and be sure to re-evaluate those factors on a periodic basis.

Performance data shown represents past performance, which is no guarantee of future results. Current performance may be higher or lower than the performance data quoted. Yield and return will vary, therefore, you may have a gain or loss when you sell your shares.


Stock markets are volatile and can decline significantly in response to adverse issuer, political, regulatory, market, or economic developments. Growth stocks can be more volatile than other types of stocks. Value stocks can continue to be undervalued by the market for long periods of time. Foreign securities are subject to interest-rate, currency-exchange-rate, economic, and political risks, all of which are magnified in emerging markets. Illiquidity is an inherent risk associated with investing in real estate and REITs. There is no guarantee the issuer of a REIT will maintain the secondary market for its shares and redemptions may be at a price which is more or less than the original price paid. Closed-end funds can trade at a discount to their NAV. Shareholders of Master Limited Partnerships may be treated as partners for tax purposes. Partnerships issue a Schedule K-1 (Form 1065) rather than a Form 1099 form for tax purposes. It lists the partner's share of income, deductions, credits, etc. Speak with your tax advisor to determine how this may affect you. A royalty trust is a type of corporation, mostly in the United States or Canada, usually involved in oil and gas production or mining. Royalty trusts may have special tax treatment, so you should consult a tax advisor on the potential tax consequences of investing in them.

News, commentary and events are from third-party sources unaffiliated with Fidelity. Fidelity does not endorse or adopt their content. Fidelity makes no guarantees that information supplied is accurate, complete, or timely, and does not provide any warranties regarding results obtained from their use.

Any data, charts and other information provided on this page are intended for research purposes to help self-directed investors evaluate many types of securities including, but not limited to common stocks, American Depository Receipts, Master Limited Partnerships, real estate investment trusts. traditional preferred stock, trust preferred securities, third-party trust certificates, convertible securities, mandatory convertible securities and other exchange-traded equity and/or debt securities. Criteria and inputs entered, including the choice to make security comparisons, are at the sole discretion of the user and are solely for the convenience of the user. Analyst opinions, ratings and reports are provided by third-parties unaffiliated with Fidelity. All information supplied or obtained from this page is for informational purposes only and should not be considered investment advice or guidance, an offer of or a solicitation of an offer to buy or sell a security, or a recommendation or endorsement by Fidelity of any security or investment strategy. Fidelity does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities. Fidelity makes no guarantees that information supplied is accurate, complete, or timely, and does not provide any warranties regarding results obtained from its use.

462499.6.0
See the Latest Features
Personalized
Get relevant information about your holdings right when you need it.
See Your Performance Click the portfolio icon to get information about stocks you own without leaving the research page.
Faster Access to Positions A shortcut to view the full list of positions in your portfolio? Yes, please! Use the ticker search box.
Add Your Own Notes Use Notebook to save your investment ideas in one convenient, private, and secure place.
Convenient For You
Research that's clear, accessible, and all in one place makes for a better experience.
One-Stop Shop See everything you need to make investment decisions right in the dashboard.
Access Anywhere No matter where you are, use the Stock Research experience across multiple devices.
New Ideas, On the Ready Find new ideas using quick links to the Stock Screener.
New Ways to Research
Discover new tools to add or diversify your existing research strategy.
StockTwits Read live tweets from the financial and investing community about the stock you're interested in.
Fundamental Analysis Save time on research by getting an overall assessment of a company's valuation, quality, growth stability, and financial health.
Recognia Technical Analysis Perfect for the technical trader—this indicator captures a stock's technical events and converts them into short, medium, and long-term sentiment.
Top Competitors See how a stock measures up by instantly comparing it to the industry average and its top four competitors.
Social Sentiment Get a sense of people's overall feelings towards a company in social media with this summary tool.
Earnings Data Monitor earnings expectations over the past three quarters and model a stock's price based on its P/E.